The largest observed difference was according to HER2 status, where HER2-positive breast cancer patients experienced a numerically greater absolute benefit from tDD EC/D in terms of cumulative BCRFS events compared to HER2-negative ones (10.9% versus 2.2% respectively, pinteraction= 0.093). Here, ERBB2 is linked to breast cancer.